Investigation Of Momordica Charantia Effects On The Rat Foot Inflammation And Behavior; experimental Model.
Abstract
Background: Pain is one of the common experiences which is unpleasant feeling that originates from any part of the body, is associated with real or possible tissue damage and linked to human past experiences. Momordica Charantia (MC) or bitter melon mainly is used all around the world for the treatment of diabetes, cancer and inflammation- associated conditions due to the existence of many bioactive ingredients which have vigorous biologic effect. The aim of our study is to investigate how low and high doses of MC plant affect foot inflammation and animal's behavior.
Materials and Methods: Sixteen male rats randomly divided into 4 experimental groups. Formaldehyde was (hind-paw formalin injection) administered for inducing pain model. After 24 hours MC (50 mg/kg, 200 mg/kg) was administered every day for five days. During the experiment, the pain thresholds, motor cortex measurements and inflamed foot volume, Locomotor Activity Test and Water Overflow Method in sequence.
Results: According to our result, when we consider the foot volume, pain threshold and motor cortex data of our control group, there is no significant difference between the beginning and the last day, while On the 7th day, the pain threshold continues to decrease as the foot volume of our animals in our positive control group does not decrease. 200 mg concentration of MC has provided a great treatment by reducing the increasing foot volume at the same time pain threshold and motor activity was in highest level at 4th day.
Conclusion: Our experiment shows that MC (200 mg/ml MC ) has high analgesic activity provides significant pain reduction and improvement in symptoms
Keywords
Formaldehyde, Inflammation, motor cortex, Momordica Charantia
Supporting Institution
yok
Project Number
yok
References
- 1. Raja, S.N., et al., The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain, 2020.
- 2. Williams, A.C., C. Eccleston, and S. Morley, Psychological therapies for the management of chronic pain (excluding headache) in adults. Cochrane Database Syst Rev, 2012. 11: p. CD007407.
- 3. Schug, S.A. and C. Goddard, Recent advances in the pharmacological management of acute and chronic pain. Ann Palliat Med, 2014. 3(4): p. 263-75.
- 4. Moseley, G.L. and H. Flor, Targeting cortical representations in the treatment of chronic pain: a review. Neurorehabil Neural Repair, 2012. 26(6): p. 646-52.
- 5. Smolen, J.S., et al., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis, 2010. 69(6): p. 964-75.
- 6. Cheney, J.E. and C.H. Collins, Formaldehyde disinfection in laboratories: limitations and hazards. Br J Biomed Sci, 1995. 52(3): p. 195-201.
- 7. Restani, P. and C.L. Galli, Oral toxicity of formaldehyde and its derivatives. Crit Rev Toxicol, 1991. 21(5): p. 315-28.
- 8. Zararsiz, I., et al., Melatonin prevents formaldehyde-induced neurotoxicity in prefrontal cortex of rats: an immunohistochemical and biochemical study. Cell Biochem Funct, 2007. 25(4): p. 413-8.
- 9. Ozen, O.A., et al., Effect of formaldehyde inhalation on Hsp70 in seminiferous tubules of rat testes: an immunohistochemical study. Toxicol Ind Health, 2005. 21(10): p. 249-54.
- 10. Nilsson, J.A., et al., Toxicity of formaldehyde to human oral fibroblasts and epithelial cells: influences of culture conditions and role of thiol status. J Dent Res, 1998. 77(11): p. 1896-903.
